NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Zynex, Inc. (“Zynex” or the “Company”) (OTC: ZYXIQ) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The Zynex Class Action Litigation? Do you, or did you, own shares of Zynex, Inc. (OTC: ZYXIQ)?Did you purchase your shares between February 25, 2021 and December 15, 2025, inclusive?Did you lose money in ...

SAN FRANCISCO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is alerting investors in CoreWeave, Inc. (NASDAQ: CRWV) to a pending class action against the company and certain of its executives. The suit alleges defendants misled the market regarding CoreWeave’s ability to scale its AI infrastructure and meet its ambitious revenue guidance. Hagens Berman is investigating the alleged claims that CoreWeave overstated its capacity to satisfy “robust” customer demand and do ...

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ramaco Resources, Inc. (“Ramaco” or the “Company”) (NASDAQ: METC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Ramaco and certain of it ...

PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Shareholder protection firm Kaskela Law announces that it is investigating potential breach of fiduciary duty claims concerning WEBTOON Entertainment Inc. (NASDAQ: WBTN) on behalf of the company’s long-term shareholders. Click here to request additional information: https://kaskelalaw.com/case/webtoon/ Recently a securities fraud complaint was filed against WEBTOON on behalf of certain investors who purchased shares of the company’s stock prior to August 9, 20 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我 2026年2月14日，立方数科股份有限公司 （简称：立方数科、ST立方，代码：300344）发布《关于收到 行政处罚决定书的公告》。 经中国证监会安徽证监局查明，立方数科等涉嫌违法的事实如下：立方数科通过开展代理业务、融资性 贸易、虚假贸易虚增营业收入、 营业成本、利润总额，导致立方数科披露的2021年至2023年年度报告 存在虚假记载。其中，2021年，虚增营业收入279，726，668.85元，占当年营业收入的50.09%，虚增营 业成本277，114，254.09元，占当年营业成本的60.61%；2022年，虚增营业收入311，855，333.46元， 占当年营业收入的51.67%，虚增营业成本305，460，743.11元，占当年营业成本的53.54%，虚增利润总 额510，390.73元，占当年利润总额绝对值的0.33%；2023年，虚增营业 ...

CoreWeave, Inc. (CRWV) Class Action Lawsuit Seeks Recovery for Investors; March 13, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP [Accessibility Statement] Skip NavigationDid you buy CRWV securities between March 28, 2025, and December 15, 2025?Affected CRWV Investor Summary- Investor Action: Contact [Kessler Topaz Meltzer & Check, LLP]([www.ktmc.com]) for recovery options at no cost to investor- Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's ability ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Beyond Meat, Inc. ("Beyond Meat, Inc." or the "Company") (NASDAQ: BYND) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Beyond Meat, Inc. investors who were adversely affected by alleged securities fraud between February 27, 2025 and November 11, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/be ...

Kyndryl Holdings, Inc. (KD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit [Accessibility Statement] Skip NavigationBENSALEM, Pa., Feb. 23, 2026 /PRNewswire/ -- [The Law Offices of Howard G. Smith] announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Kyndryl Holdings, Inc. ("Kyndryl" or the "Company") (NYSE: [KD]).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN KYNDRYL HOLDINGS, INC. (KD), CONTACT THE LAW OFF ...

Core Points - A securities fraud class action lawsuit has been filed against CoreWeave, Inc. for alleged misstatements and omissions regarding its operational capabilities and financial risks [2][6] - The class period for the lawsuit is from March 28, 2025, to December 15, 2025, with a lead plaintiff deadline set for March 13, 2026 [2][6] Allegations - The lawsuit claims that CoreWeave overstated its ability to meet customer demand for its services [4][6] - It is alleged that the company understated its reliance on a single third-party data center supplier, which poses significant operational risks [4][6] - The complaint also states that CoreWeave misrepresented the financial risks associated with this dependency, including revenue exposure [4][6] - Public statements made by the company were claimed to be materially false and misleading, leading to inaccurate revenue expectations [4][6] Investor Actions - Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for recovery options and to discuss their legal rights [4][5] - Investors can file to be a lead plaintiff by the deadline of March 13, 2026, or choose to remain an absent class member [7][8] - The lead plaintiff will represent the interests of all class members in the litigation process [8]

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. concerning allegations of securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves claims that uniQure and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until April 13, 2026, to request to be appointed as Lead Plaintiff if they purchased or acquired uniQure securities during the Class Period [2]. Group 2: Company Developments - On November 3, 2025, uniQure announced feedback from the U.S. FDA regarding its investigational gene therapy AMT-130 for Huntington's disease, indicating a shift in the FDA's stance on the adequacy of data from Phase I/II studies for a Biologics License Application (BLA) submission [4]. - Following this announcement, uniQure's stock price dropped by $33.40 per share, or 49.34%, closing at $34.29 per share on the same day [4].